Photo Gallery

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • WJPPS MAY ISSUE PUBLISHED
  • MAY 2020 Issue has been successfully launched on 1 May 2020.

Abstract

EFFECT OF GLIMEPIRIDE ON REDUCING BLOOD SUGAR LEVELS IN MALE WHITE MICE WITH DIABETES MELLITUS WITH COMPLICATIONS OF LIVER DYSFUNCTION

Lili Sartika, Helmi Arifin, Almahdy A. and Harrizul Rivai*

ABSTRACT

This research has been carried out to determine the effect of glimepiride on reducing blood sugar in diabetic white male mice with complications of liver dysfunction. Diabetic mice are made by injecting alloxan. Diabetic mice with complications of liver dysfunction are made by injecting alloxan and carbon tetrachloride. Mice were divided into seven groups, namely positive control groups and six groups of test preparations given glimepiride for 15 days (1, 2, and 4 mg/kg BW). The results showed that administration of glimepiride 1 mg, 2 mg and 4 mg in the diabetic and diabetic-liver dysfunction group decreased blood sugar levels were 58.3 mg/dL and 41.2 mg/dL; 93.5 mg/dL and 67.1 mg/dL; 118.93 mg/dL and 89.6mg/dL. Decrease in blood sugar levels on day 5, day 10 and day 15 of the diabetes group dose of 1 mg, 2 mg and 4 mg were 61 mg/dL, 86.20 mg/dL and 133.20 mg/dL, the diabetic-liver dysfunction group respectively were 69.8 mg/dL, 133.2 mg/dL and 153.80 mg/dL. In diabetic-liver dysfunction mice the decrease in glucose levels in glimepiride blood 1 mg respectively was 27 mg/dL, 44 mg/dL and 52.6 mg/dL, 2 mg respectively was 44 mg/dL, 55 mg/dL and 102.2 mg/dL, 4 mg respectively were 57.8 mg/dL, 102.2 mg/dL and 108.8 mg/dL. From the results of this study, it can be concluded that the mechanism of action of glimepiride is affected by the length of treatment and is not influenced by the pathological disease.

Keywords: Diabetes mellitus, liver dysfunction, glimepiride, alloxan, carbon tetrachloride, blood sugar.


[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More